Curated News
By: NewsRamp Editorial Staff
March 10, 2026

Soligenix's Behcet's Disease Treatment Gets UK Promising Medicine Designation

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • Soligenix's SGX945 gains UK PIM designation, positioning it ahead in rare disease treatment with potential market advantage over existing Behcet's Disease therapies.
  • The UK PIM designation for SGX945 is based on Phase 2 data showing improved benefit-risk profile and is the first step toward early patient access schemes.
  • This designation accelerates access to promising treatment for Behcet's Disease patients, offering hope for better management of this rare inflammatory disorder worldwide.
  • Soligenix's dusquetide represents a novel approach targeting rare inflammatory diseases, expanding treatment options beyond the company's existing photodynamic therapy pipeline.

Impact - Why it Matters

This development matters because Behcet's Disease is a rare, chronic inflammatory disorder that can cause painful mouth and genital sores, skin lesions, and potentially serious complications affecting the eyes, joints, and blood vessels. Current treatment options are limited and often involve immunosuppressants with significant side effects. The PIM designation represents a critical step toward potentially faster access to innovative therapies for patients with this debilitating condition. For the broader rare disease community, this regulatory pathway demonstrates how promising treatments can reach patients more quickly when they address serious unmet medical needs. The designation also validates Soligenix's innovative approach to treating inflammatory diseases and could accelerate development timelines for similar rare disease therapies globally.

Summary

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has achieved a significant regulatory milestone with its drug candidate SGX945 (dusquetide) receiving Promising Innovative Medicine (PIM) designation from the U.K. Medicines and Healthcare Products Regulatory Agency. This designation specifically targets the treatment of Behcet's Disease, a rare inflammatory disorder, and represents the crucial first step toward potential inclusion in the U.K.'s Early Access to Medicines Scheme. The PIM designation was granted based on promising Phase 2 clinical data suggesting that dusquetide may offer a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients suffering from this serious condition.

The company's Specialized BioTherapeutics business segment is actively developing multiple innovative therapies, including HyBryte™ (SGX301) for cutaneous T-cell lymphoma, which has completed a second Phase 3 study and is moving toward potential worldwide commercialization. Their development pipeline also includes expansion of synthetic hypericin (SGX302) into psoriasis treatment, dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer patients, and the newly designated SGX945 for Behcet's Disease. To view the full press release, visit https://ibn.fm/N8oN5, where you can find comprehensive details about this important development.

Soligenix's broader portfolio extends to their Public Health Solutions business segment, which includes vaccine development programs for threats such as ricin toxin, filoviruses (including Marburg and Ebola), and CiVax™ for COVID-19 prevention. These programs utilize the company's proprietary ThermoVax® heat stabilization platform technology and have received substantial government support from agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX, providing ongoing access to developments in their innovative therapeutic pipeline.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Soligenix's Behcet's Disease Treatment Gets UK Promising Medicine Designation

blockchain registration record for this content.